Clinical Trials
31 trialsBrightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
LEADER
National Taiwan University Hospital
TOMOREP
Institut Bergonié
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
ANNOUNCE
Eli Lilly and Company
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Boehringer Ingelheim
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Columbia University
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
STRASS
European Organisation for Research and Treatment of Cancer - EORTC
SEAL
Karyopharm Therapeutics Inc
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Grupo Espanol de Investigacion en Sarcomas
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
National Cancer Institute (NCI)
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Memorial Sloan Kettering Cancer Center
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Vector Oncology
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute